Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread.